Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. Batich, K.A., Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. 917-322-2571, Internet Explorer presents a security risk. Request a free trial. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Immunomic Therapeutics is a biotech company committed to patients. Melody Carey Immunomic Therapeutics General Information. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). 2017 Aug;47:85-92. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Of special note are the following publications: To browse the literature, please see the curated list at PubMed. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. The company was founded in 2005 and is based in Lancaster, Pennsylvania. 2003 Sep 26;278(39):37926-36. All content is posted anonymously by employees working at Immunomic Therapeutics. 28 Employees . Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Immunomic Therapeutics' nucleic acid vaccines have the . 2006 Aug 15;177(4):2265-75. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. 2017 Jun 12:1-10. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. J Biol Chem. ITI maintains its headquarters in Rockville, Maryland. Coordinates: 245831.9N 1213154.0E. ITI-ID Candidate Multiple infectious diseases. 438 followers 429 connections. ROCKVILLE, Md., October 10, 2022--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. April 23, 2020 04:00 PM Eastern Daylight Time. ITI Company: Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. For more information, please visit www.immunomix.com. Melody Carey We provide a professional and challenging work environment . Rockville's Immunomic Therapeutics Inc. is on track to go public later this year, after Covid-19 threw a wrench in the vaccine maker's initial timeline. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. Background. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI") a privately-held clinical-stage biotechnology company pioneering the . ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. 717-327-1822, ITI Media: ITI maintains its headquarters in Rockville, Maryland. Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. CONTACT US. We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies. Animal Health All. Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. ITI-1000 GBM - Cell Therapy. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. Nature. Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. Clin Cancer Res. Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. Katie Pearce. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. Companies. Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. ITI-2000 HPV+ Tumors. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. Report this profile . UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. This feature is in beta and may change with future updates. As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. ICT has established a broad portfolio of CAR-T products to treat cancer patients. Harnessing the immune system to achieve deep and durable clinical responses in cancer. November 30, 2021, 7:01 PM UTC. We provide a professional and challenging work environment . ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson). Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). Where the organization is headquartered (e.g. ITI-3000 Merkel Cell Carcinoma - pDNA. View contacts for Immunomic Therapeutics to access new leads and connect with decision-makers. all maps fatal bullet; who is running for senate in maryland 2022 Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. Founded Date 2015. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. While research is the essential engine that drives our technology forward, our efforts in process development, manufacturing management, and regulatory affairs are critical factors that advance the Immunomic Therapeutics vision. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. The company was founded in 2005 and is based in Lancaster, Pennsylvania. We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. Active, Closed, Last funding round type (e.g. No.93, Zhongyang Rd., Xindian Dist., New Taipei City 231, Taiwan. Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. To explore Immunic Therapeutics's full profile, request access. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Last Funding Type Venture - Series Unknown. Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. 2017 Apr 15;23(8):1898-1909. Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). Great people . Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. What is health insurance like at Immunomic Therapeutics. Active, Closed, Last funding round type (e.g. Join to connect Immunomic Therapeutics, Inc. Mount Saint Mary's College. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . This day-long event includes an Advocacy Summit Liked by Priscilla Fussell ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population.

Dyson V11 Blue Light Flashing 10 Times, Percy Jackson Kidnapped By Luke Fanfiction Lemon, Articles I